KIT
Hematologic System · Hematopoiesis, Erythropoiesis & Iron Homeostasis
How can KIT be involved in normal cells and also be a cancer target?
KIT makes a receptor activated by stem cell factor, a signal that influences cell growth and survival. A drug-target role in a particular tumor depends on that tumor's findings, not simply on having KIT in a DNA report.
- Common Gene Name
- KIT proto-oncogene, receptor tyrosine kinase
- NCBI Gene ID
- 3815
- Chromosome
- 4
Clinical Evidence Status
Established disease relationshipTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (7 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| gastrointestinal stromal tumor | ClinGen gene-disease validity | Definitive | Autosomal dominant | View source 2020-01-14 |
| Piebaldism | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2018-10 | |
| Core binding factor acute myeloid leukemia | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2018-10 | |
| Systemic mastocytosis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2018-10 | |
| Avapritinib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Imatinib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Midostaurin (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Hematologic System